CurrentCentenePolicy CP.PHAR.189

Ibandronate Injection (Boniva) (PDF)

Defines medical necessity criteria, approval durations, contraindications, dosing, and coding guidance for ibandronate sodium injection for treatment of postmenopausal osteoporosis across Centene lines of business (Commercial, HIM, Medicaid).

Policy Summary

PayerCentene

PolicyIbandronate Injection (Boniva) (PDF)

Policy CodePolicy CP.PHAR.189

Change TypeRevised (annual reviews / approval duration change)

Effective DateNov 15, 2017

Next Review Date

Key ActionProvider must submit documentation supporting that the member has met all approval criteria and document a 12-month trial of an oral bisphosphonate (generic alendronate preferred) unless contraindicated; IL HIM requests bypass step therapy per IL HB 5395.

SourceLink

POLICY UPDATE CHANGES

1Q 2024 annual review added criteria that member must use generic ibandronate injection and clarified failure of 'generic' alendronate is preferred; clarified dosage regimens in Appendix B per PI.

Revised initial approval duration to 12 months for Medicaid/HIM and added step therapy bypass for IL HIM per IL HB 5395 (noted 06.26.25).

1Q 2026 annual review removed redirection to generic ibandronate as branded Boniva has been discontinued.

1Q 2022/2023/2025 annual reviews: no significant changes; references reviewed and updated.

1Covered Indication (PMO)

3Approval duration variants

1HCPCS drug code referenced

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Policy stance: covered with criteria for ibandronate sodium injection when used for treatment of postmenopausal osteoporosis (PMO) and all approval criteria are met. Effective date of this clinical policy is 11.15.17 and the last policy review was on 02.26. Scope: defines medical necessity criteria, approval durations, contraindications, dosing, and coding guidance for ibandronate sodium injection across Centene lines of business (Commercial, HIM, Medicaid).

Applicable Codes

Drug HCPCSHCPCSCovered

J1740

Injection, ibandronate sodium, 1 mg

Coding and billing: HCPCS code J1740 represents injection, ibandronate sodium, 1 mg unit and is billed per mg. Providers must follow the policy dose/billing limits which restrict dosing to a maximum of 3 mg every 3 months and no more than 1 syringe every 3 months. Appendix B and the Dosage/Administration section clarify the approved regimen of 3 mg IV every 3 months and product availability as a 3 mg/3 mL single-dose prefilled syringe.

Provider Actions & Prior Authorization

Prior Authorization

Documentation for prior authorization

Providers must submit documentation (such as office chart notes, lab results, or other clinical information) supporting that the member has met all approval criteria when requesting prior authorization for ibandronate injection.

J1740

Step Therapy

Step therapy requirement

Step therapy requires failure of a 12-month trial of an oral bisphosphonate (see Appendix B); generic alendronate is preferred, unless contraindicated or clinically significant adverse effects are experienced. Prior authorization may be required. Exception: Illinois HIM requests do not have the step therapy requirement as of 2026-01-01 per IL HB 5395.

Illinois HIM exception per IL HB 5395 effective 2026-01-01

Billing Rule

Dose/billing limits

Do not authorize or bill for doses exceeding 3 mg per 3 months or for more than 1 syringe per 3 months. Note that J1740 is billed per mg (1 mg units).

J1740 billed per mg (1 mg units)

Documentation Required

Continued therapy documentation

For continued therapy, the provider must document that the member is responding positively to therapy and meets continuity or previous-criteria provisions (e.g., currently receiving medication via Centene benefit or previously met initial approval criteria). Refer to state-specific continuity addendums CC.PHARM.03A and CC.PHARM.03B where applicable.

Clinical Evidence & References

Evidence and references supporting the policy include the FDA Prescribing Information: Ibandronate Sodium Injection Prescribing Information, Apotex Corp.; October 2025. Guideline and literature references cited include Endocrine Society guideline updates, AACE/ACE clinical practice guidelines, ACP living guideline, and USPSTF recommendations and related osteoporosis management literature. The policy notes that safety and effectiveness are based on one-year clinical data and recommends that duration of therapy be reassessed periodically.

Background

Background: Ibandronate injection is a bisphosphonate indicated for treatment of osteoporosis in postmenopausal women. In this population, ibandronate injection increases bone mineral density (BMD) and reduces the incidence of vertebral fractures. The safety and effectiveness of ibandronate sodium injection for osteoporosis are based on clinical data of one year duration; the optimal duration of use has not been determined, and the need for continued therapy should be re-evaluated on a periodic basis.

Revision History

1Q 2024material_change

1Q 2024 annual review added criteria that member must use generic ibandronate injection; clarified failure of 'generic' alendronate is preferred; clarified dosage regimens in Appendix B per PI.

06.26.25material_change

Revised initial approval duration to 12 months for Medicaid/HIM and added step therapy bypass for IL HIM per IL HB 5395.

1Q 2026non_material_changeLatest

1Q 2026 annual review removed redirection to generic ibandronate as branded Boniva has been discontinued; references reviewed and updated.

1Q 2022/2023/2025non_material_change